Pharma Focus Asia

GlaxoSmithKline Pharmaceuticals plans to set up pharma plant in Bengaluru, India


GlaxoSmithKline Pharmaceuticals (GSK Pharma) will invest Rs 1000 crore for greenfield manufacturing facility at Vemgal near Bengaluru, India.


The greenfield facility, which will have an installed capacity of over 9 billion tablets and capsules per year, is expected to be operational by 2017.

The new site, which represents up to Rs 1,000 crore in investments, will be the first greenfield pharma site GSK has built across the globe over the past 10 years.The new unit is part of the strategic plan to rationalize, streamline and reduce costs in the supply network, whilst increasing capacity to meet the growing demands for important medicines, the company said.

GSK India is also upgrading the Nashik site by investing in infrastructure across all areas with special focus on good manufacturing practices (GMP), safety and sustainability.

The company's Nashik facility, continuing its journey on roadmap of long-term strategy, has made significant progress in terms of building capability. It has completed enhancement of the existing Eltroxin facility in safety standards. The unit is ready to launch new products in Bactroban creams early next year.


Company NameGlaxoSmithKline Pharmaceuticals
LocationBengaluru, India
TypeManufacturing Facility
Estimated CostRs 1000 crore
Operations Starts2017

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference